共 50 条
- [31] Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trialJAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (06) : 551 - 559Oyama, MasafumiSugiyama, TakayukiNozawa, MasahiroFujimoto, KiyohideKishida, TakeshiKimura, GoTokuda, NoriakiHinotsu, ShiroShimozuma, KojiroAkaza, HideyukiOzono, Seiichiro
- [32] Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Gruenwald, V.Karakiewicz, P. I.Bavbek, S. E.Miller, K.Machiels, J. H.Lee, S.Larkin, J. M. G.Bono, P.Rha, S. Y.Castellano, D. E.Blank, C. U.Knox, J. J.Hawkins, R.Yuan, R. R.Rosamilia, M.Booth, J. L.Bodrogi, I.
- [33] Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitorsTUMOR BIOLOGY, 2016, 37 (04) : 4919 - 4927Park, InkeunCho, Yong MeeLee, Jae-LyunAhn, Jin-HeeLee, Dae-Ho
- [34] Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitorINTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (07) : 740 - 740Mizuno, RyuichiMiyajima, AkiraOya, Mototsugu
- [35] Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label StudyCLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2020, 12 : 21 - 33Wang, XichengZhou, JianfengLi, YanGe, YupingZhou, YanpingBai, ChunmeiShen, Lin
- [36] Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Nadal, RosaAmin, AsimGeynisman, Daniel M.Voss, Martin HennerWeinstock, MatthewDoyle, JaimeZhang, ZheViudez, AntonioPlimack, Elizabeth R.McDermott, David F.Motzer, RobertRini, Brian I.Hammers, Hans J.
- [37] DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b studyAMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 739 - 749Huntington, Scott F.Schuster, Stephen J.Ding, WeiKoehler, Amber B.Brander, Danielle M.Rosenthal, Allison C.Leis, Jose F.Tun, Han W.Moustafa, Muhamad AlhajIqbal, MadihaHe, WeiKearney, Albert S.McKinlay, Timothy P.Gui, MinMato, Anthony R.
- [38] Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutationJOURNAL OF THORACIC DISEASE, 2013, 5 (05) : 585 - 592Fang, WenfengZhang, JianweiLiang, WenhuaHuang, YanYan, YueWu, XuanHu, ZhihuangMa, YuxiangZhao, HongyunZhao, YuanyuanYang, YunpengXue, CongZhang, JingZhang, Li
- [39] Nodular Regenerative Hyperplasia of the Liver Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor in a Patient With Metastatic Renal Cell CarcinomaJCO PRECISION ONCOLOGY, 2023, 7Rudolph, ShannonLi, MingjiaGheeya, JineshZimmerman, DanielleYin, MingClinton, Steven K.Parwani, Anil V.Yang, Yuanquan